

June 6, 2013

To All Shareholders

Shionogi & Co., Ltd.
Isao Teshirogi
President and CEO

Partial Correction to Notice of Convocation of the 148th Annual General Meeting of Shareholders

Shionogi & Co., Ltd. announced today via its website the partial correction to the content of Business Report included in “Notice of Convocation of the 148th Annual General Meeting of Shareholders”. The corrected part is as stated below and the correction is shown by underlined text.

**Corrected part:
Page 6, 2) Development Activities, 1. Approval**

[Before correction]

1. Approval

【Product Name】	Category (Administration)	Indication	Country: Period
Metreleptin	Recombinant human leptin (genetic recombination) <u>(Oral)</u>	Lipodystrophy	Japan: March, 2013

[After correction]

1. Approval

【Product Name】	Category (Administration)	Indication	Country: Period
Metreleptin	Recombinant human leptin (genetic recombination) <u>(Injection)</u>	Lipodystrophy	Japan: March, 2013

###